(Stewardson et al., Thyroid, 2023)
ThyroSPEC underwent clinical validation on 64 AUS/FLUS and 33 FN/SFN consecutive CytoLyt FNAC with histologic diagnoses, data presented at the 2019 American Thyroid Association Annual Meeting (Stewardson et al., ATA, 2019).
For 26% pre-test risk of malignancy in the AUS/FLUS category:
| Sensitivity: | 55% |
| Specificity: | 88% |
| Positive Predictive Value (PPV): | 61% |
| Negative Predictive Value (NPV): | 85% |
For 43% pre-test risk of malignancy in the FN/SFN category:
| Sensitivity: | 38% |
| Specificity: | 75% |
| Positive Predictive Value (PPV): | 54% |
| Negative Predictive Value (NPV): | 62% |